Bay­er and AskBio ex­pand grand gene ther­a­py am­bi­tions with new Parkin­son's pro­gram, top sci­en­tist

It on­ly took 20 years, but Jude Samul­s­ki is fi­nal­ly turn­ing AskBio in­to a gene ther­a­py be­he­moth in the hills of North Car­oli­na.

The now Bay­er-owned biotech an­nounced Thurs­day they were bring­ing over the clin­i­cal team from Brain Neu­rother­a­py Bio, com­plet­ing a buy­out tipped in De­cem­ber and adding clin­i­cal pro­grams in Parkin­son’s and mul­ti­ple sys­tem at­ro­phy to an al­ready large pipeline.

AskBio launched Brain­Neu­Bio in 2018, a move con­sis­tent with Samul­s­ki’s long-run­ning strat­e­gy of spin­ning out promis­ing pro­grams, which led to the Bam­boo Ther­a­peu­tics and Pfiz­er’s Duchenne Gene Ther­a­py pro­gram, as well as a he­mo­phil­ia pro­gram now owned by Take­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER